top menu

VISION COMMUNITY RECOGNIZES JULY AS DRY EYE AWARENESS MONTH, HOSTING VIRTUAL CONGRESSIONAL BRIEFING ABOUT DRY EYE DISEASE

(Washington, D.C.) The Alliance for Eye and Vision Research (AEVR) and the Tear Film & Ocular Surface Society (TFOS) are excited to announce the seventh annual Dry Eye Awareness Month Congressional Briefing this summer.

July has been recognized as Dry Eye Awareness Month since 2017 when the Tear Film & Ocular Surface Society’s landmark Dry Eye Workshop II (TFOS DEWS II™) Report was published in The Ocular Surface journal. As part of Dry Eye Awareness Month, the vision community has organized events to increase awareness about the growing global impact of dry eye disease. As part of these events, the vision community is raising awareness with policymakers about dry eye, and the need to address this growing condition through research to improve patient outcomes.

As one of the most frequent causes of patient visits to eye care providers, dry eye disease needs to remain a priority. The National Institutes of Health (NIH), particularly through the National Eye Institute (NEI), funds research into the causes and potential treatments of dry eye disease and continues to support research into innovative treatments and therapies that can support patients who experience this condition.

On July 13th, AEVR, in conjunction with TFOS, will host its virtual Congressional Briefing entitled Food for thought: Dry eye disease, from noon to 1 pm ET. The Briefing features a panel of experts who will speak to risk factors for, and ocular pain of, dry eye disease, as well as how research is vital to develop innovative treatments for dry eye disease. To register for the briefing, click here.

Dry eye disease remains a global epidemic affecting more than 40 million people in the United States alone. It occurs when the eye does not produce tears properly or when the tears are not of the correct consistency and evaporate too quickly. For some people, it feels like a speck of sand in the eye or a stinging or burning sensation that does not go away. For others, dry eye can become a painful chronic, and progressive condition that leads to blurred vision or even vision loss if it goes untreated due to inflammation that can cause ulcers or scars on the cornea—the clear surface of the eye. Moderate-to-severe dry eye is associated with significant quality-of-life consequences such as pain, role limitations, low vitality, poor general health, and depression. Although dry eye disease has no cure, its signs and symptoms can be managed. A lifestyle change, if warranted, may also help in this effort to a great degree.

Although researchers have long known about age, sex, and gender as factors, they are now discovering ethnic and racial differences, and that dry eye impacts younger patients. It can have many causes, including environmental exposure; poor nutrition; side-effects from medications or eye surgery; lid disorders; immune system diseases such as Sjögren Syndrome, lupus, or rheumatoid arthritis; contact lens wear; cosmetic use; aesthetic procedures; and an increasingly common cause—staring at computer or smartphone screens for too long.

The vision community members recognizing July 2022 as Dry Eye Awareness Month and engaging in awareness and educational activities include:

Alliance for Eye and Vision Research
American Academy of Ophthalmology
American Academy of Optometry
American Optometric Association
Association for Research in Vision and Ophthalmology

Healthy Women
Prevent Blindness
Research to Prevent Blindness
Sjögren’s Foundation
Tear Film & Ocular Surface Society
Women’s Eye Health

AEVR and TFOS thank the sponsors and supporters that are helping to bring this Congressional Briefing to fruition, including: Alcon, Bausch+Lomb, Allergan, Genentech, Association for Research and Vision for Ophthalmology, Johnson and Johnson Vision, Novartis, and Research to Prevent Blindness.

About TFOS
Founded in 2000, the Tear Film & Ocular Surface Society is a world leader in eye health education headquartered in Boston. A 501(c)3 non-profit foundation, TFOS is dedicated to advancing the research, literacy, and educational aspects of the scientific field of the eye’s surface. More information about the TFOS DEWS II™ Report is available at www.tearfilm.org

About AEVR
Founded in 1993, the Alliance for Eye and Vision Research is a 501(c)3 non-profit foundation dedicated to education about the importance of federal funding for eye and vision research. Information about the July 10 Congressional events is available at www.eyeresearch.org

 

 

   
foto 1

Donate to TFOS

TFOS is a 501(c)(3)
non-profit organization.

With support of friends like you,
TFOS has seen record successes in
advancing vision around the
globe
. Every level of support makes
a difference! Please click here:

read

TFOS & Amazon Smile

When customers shop on AmazonSmile, the AmazonSmile
Foundation
will donate 0.5% of the
price of eligible purchases to the
charitable organizations selected by
customers. Please help TFOS by
shopping on Amazon from this link:

read

foto 2
   
   
TFOS logo

TFOS is a world leader in eye health education.

Over the last several decades, a significant international research effort has been directed towards understanding the composition and regulation of the pre-ocular tear film, a movement largely motivated by the recognition that the tear film plays a critical role in maintaining corneal and conjunctival integrity, protecting against microbial challenge and preserving visual acuity.

Additionally, this research has been stimulated by the knowledge that alteration or deficiency of the tear film, which occurs in countless individuals throughout the world, may lead to ocular surface desiccation, corneal ulceration and perforation, increased incidence of infectious disease and potentially pronounced visual disability and blindness. TFOS was founded and incorporated as a non-profit organization to facilitate forward momentum in tear film and ocular surface research. The Society’s Global Ambassador and membership programs foster collaboration among scientists, clinicians and industry professionals to help the world see better.

   
  read
   
 
TFOS BRAND
 

TFOS is honored that doctors and companies around the world are sharing our content and education about ocular surface diseases. Please note that TFOS does not endorse or promote any commercial products or services. Placing the TFOS logo, TFOS name or TFOS DEWS II trademark on products or services is a misappropriation of the TFOS brand and a violation of our organizational policies.

One of the key values of TFOS is our neutrality. Endorsing commercial products or services can jeopardize our mission.

If companies are interested in partnering with TFOS, please contact Amy Gallant Sullivan for more details.

 
 

Follow TFOS on Twitter & Share the news as it happens! Tweet us your updates!
@Eyeppl

Corporate Advisory Board
Alcon, CooperVision, Dompé
I-Med Pharma, Johnson & Johnson Vision
Novartis and SINQI

Tear Film & Ocular Surface Society
www.tearfilm.org